Item 1.01. Entry into a Material Definitive Agreement.
On August 4, 2009, Immunomedics, Inc., a Delaware corporation (the "Company"),
received a letter, dated July 30, 2009, from UCB, S.A. ("UCB") stating that UCB
has identified a third party manufacturer for epratuzumab and therefore relieved
the Company of its obligation to supply to UCB Licensed Product (as defined in
that certain Development, Collaboration and License Agreement, dated as of
May 9, 2006, between the Company and UCB (the "Agreement")) pursuant to
Section 4.3 of the Agreement for use in clinical trials for systemic lupus
erythematosus. All other terms of the Agreement remain in effect.
Add
IMMU to Portfolio
Set Alert
Email to a
Friend